Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
S2Medical ABOSTO:S2M +4.00% Return-on-Tangible-Equity is -989.67% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 759 Medical Devices & Instruments companies, S2Medical AB ranks worse than 97.63% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. S2Medical AB's annualized net income for the quarter that ended in Dec. 2025 was kr-20.51 Mil. S2Medical AB's average shareholder tangible equity for the quarter that ended in Dec. 2025 was kr2.07 Mil. Therefore, S2Medical AB's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -989.67%.
The historical rank and industry rank for S2Medical AB's Return-on-Tangible-Equity or its related term are showing as below:
OSTO:S2M'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -494.84 Med: -142.15 Max: -49.08
Current: -494.84
During the past 10 years, S2Medical AB's highest Return-on-Tangible-Equity was -49.08%. The lowest was -494.84%. And the median was -142.15%.
OSTO:S2M's Return-on-Tangible-Equity is ranked worse than 97.63% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs OSTO:S2M: -494.84
S2Medical AB (OSTO:S2M) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
S2Medical AB Return-on-Tangible-Equity Related Terms
S2Medical AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for S2Medical AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:S2M vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, S2Medical AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S2Medical AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S2Medical AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where S2Medical AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -989.67% mean?
S2Medical AB (OSTO:S2M) has a Return-on-Tangible-Equity of -989.67% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on S2Medical AB and its competitors. According to the industry distribution chart, S2Medical AB ranks #741 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 97.6%.
Is S2Medical AB's Return-on-Tangible-Equity too high?
S2Medical AB's current Return-on-Tangible-Equity is -989.67%. Based on the distribution chart, S2Medical AB ranks #741 out of 759 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does S2Medical AB's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, S2Medical AB ranks #741 out of 759 companies for Return-on-Tangible-Equity. This places S2Medical AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on S2Medical AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S2Medical AB's current Return-on-Tangible-Equity is -989.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
Based on GuruFocus' analysis, S2Medical AB (OSTO:S2M) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.01, compared to a current price of kr0.01 — trading 48% below its estimated fair value. The current Return-on-Tangible-Equity is -989.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For S2Medical AB (OSTO:S2M), the current Return-on-Tangible-Equity is -989.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:S2M has been successfully added to your 
